A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

摘要: The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and telaprevir develop consensus recommendations optimal use these agents for treatment patients with chronic hepatitis C virus (HCV) infection. An expert panel seven leading authorities in viral was convened establish disseminate a practical guide best practices incorporating into therapy HCV infection both treatment-naive treatment-experienced patients. topics covered include selecting candidates boceprevir- or telaprevir-based treatments, predictors response early kinetics, response-guided approaches, on-treatment management strategies optimize likelihood minimize risk drug resistance, adverse effects during key considerations special populations. incorporated available evidence how should be used setting. They indicated regimens may differ according baseline factors, such as presence cirrhosis when need modified stopped altogether because events poor virologic response. This will serve valuable resource clinicians embarking new paradigm combination peginterferon/ribavirin genotype 1